2025.07.01
In the rapidly evolving field of cell and gene therapy, maintaining cellular integrity post-thaw is non-negotiable. Kryogene™ Cell Freezing Media - CGT (CFM-CGT) redefines cryopreservation by ensuring immune cells retain their critical markers and functionality, even after long-term storage.
Immune cell therapies rely on specific surface markers (e.g., CD34+, CD3, CD56) to target diseases effectively. Traditional cryopreservation methods risk altering these markers, compromising therapeutic efficacy. Kryogene™ CFM-CGT addresses this by leveraging USP-compliant, serum-free formulations that eliminate animal-derived components and minimize endotoxins (<0.5 EU/mL).
· HSPCs (CD34+ Cells): Post-thaw, Kryogene™ maintains >95% viability and preserves CD34+ purity, high CD34+ content, and CD34+/CD90+ populations, enabling robust expansion (TNC fold increase: 3,000–4,000×).
· T Cells & PBMCs: Retains cytokine release capacity (IFN-γ, IL-2, TNF-α) and T-cell subsets (CD4+/CD8+) post-stimulation, matching fresh-cell functionality.
· NK Cells & Macrophages: Sustains ADCC killing efficiency against tumor targets (e.g., SK-BR3) and surface markers (CD68+, CD11b+) after differentiation.
· MSCs: Adipose- and umbilical-derived MSCs show unchanged differentiation potential (osteogenic, adipogenic) and stemness markers (CD73+, CD90+, CD105+) post-cryo.
Kryogene™ CFM-CGT’s optimized cryoprotectant cocktail prevents ice-crystal damage and oxidative stress, ensuring cells not only survive but thrive. In septic mouse models, CFM-CGT-cryopreserved MSCs boosted survival rates by 42.3%—outperforming conventional solutions.
Manufactured under cGMP guidelines with full FDA DMF (#040563) compliance, Kryogene™ delivers batch-to-batch consistency for IND/BLA submissions. Its pre-formulated DMSO eliminates manual errors, while ultra-low endotoxin levels ensure direct clinical applicability.
Uncompromised Cells, Unmatched Therapies
Choose Kryogene™ CFM-CGT to safeguard your cell products’ identity, potency, and efficacy—from freezer to patient.
Learn how Kryogene™ is advancing the future of cell therapies at https://www.milecell-bio.com.
